普瑞巴林与加巴喷丁治疗坐骨神经痛:随机双盲交叉试验方案
本研究为前瞻性随机双盲双模拟交叉试验,头对头比较普瑞巴林与加巴喷丁治疗慢性坐骨神经痛的疗效,主要结局为视觉模拟量表(VAS)和Oswestry功能障碍指数(ODI)。目标剂量为加巴喷丁400-800 mg每日三次、普瑞巴林150-300 mg每日两次,各用药8周,洗脱期1周。假设普瑞巴林优效,需样本量n=38(80%把握度,5%I类错误率)。
要点
- 头对头比较普瑞巴林与加巴喷丁对慢性坐骨神经痛的疗效,填补直接比较证据空白。
- 主要结局为VAS和ODI,目标剂量加巴喷丁400-800 mg每日三次、普瑞巴林150-300 mg每日两次。
- 采用意向性治疗分析,样本量n=38(80%把握度,5%I类错误率)。
核心结论
- 本研究将建立普瑞巴林与加巴喷丁在减轻坐骨神经痛患者疼痛方面的疗效比较,并增进对可选治疗方案的了解。
研究设计与样本
- 前瞻性、随机、双盲、双模拟交叉试验,纳入年龄>18岁、单侧慢性坐骨神经痛且影像学确认相应神经压迫/刺激的患者。
- 排除孕妇、重大器官疾病者或肌酐清除率<60 ml/分钟者,患者继续当前止痛药且既往30天剂量稳定。
- 每种药物滴定至目标剂量(加巴喷丁400-800 mg每日三次,普瑞巴林150-300 mg每日两次)并服用8周,第一种药物停药后经1周洗脱期再交叉。
- 假设普瑞巴林优效,所需样本量n=38(80%把握度,5%I类错误率),采用意向性治疗分析。
主要发现
- 原文未报告研究结果。
关键数值与推荐
- 主要结局采用视觉模拟量表(VAS)和Oswestry功能障碍指数(ODI)评估药物疗效。
- 健康控制源量表(Health Locus of Control Scale)结果及副作用频率/严重程度用于评估心理功能。
临床怎么用
- 原文未报告临床实践推荐。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is currently an absence of high-grade evidence regarding the treatment of chronic sciatica (CS). Whilst gabapentin (GBP) and pregabalin (PGB) are both currently used to treat CS, equipoise exists regarding their individual use. In particular, no head-to-head study of GBP and PGB in CS exists. Despite equipoise, most countries' formulary regulatory authorities typically favour one drug for subsidy over the other. This hinders interchange wherever the favoured drug is either ineffective or not tolerated. The primary aim of this study is to conduct a head-to-head comparison of the efficacy of PGB versus GBP for CS based on outcomes on a visual analogue scale (VAS) and the Oswestry Disability Index (ODI). METHODS/DESIGN: We are conducting a prospective, randomised, double-blind, double-dummy cross-over study. Included patients will be over 18 years old and have unilateral CS with radiological confirmation of corresponding neural compression/irritation. Pregnant women, those with major organ disease, or those with creatinine clearance < 60 ml/minute will be excluded. Patients will continue their current pain medication at study onset, conditional upon dosage consistency during the prior 30 days. Each drug will be titrated up to a target dose (GBP 400-800 mg three times daily, PGB 150-300 mg twice daily) and taken for 8 weeks. The first drug will then be ceased; however, cross-over will be deferred pending a 1-week washout period. Drug efficacy will be assessed using the VAS and ODI. Results of the Health Locus of Control Scale and side effect frequency/severity will be used to determine psychological functioning. Assuming the hypothesis that PGB will display a superior effect, the sample size required is n = 38 with 80% power and a 5% type I error rate. Results will be analysed via intention-to-treat methodology. DISCUSSION: This study will establish the efficacy of PGB compared with GBP in reducing pain in people with sciatica and lead to greater understanding of the treatment options available. TRIAL REGISTRATION: Australian and New Zealand Clinical Trials Registry, 12613000559718 . Registered on 17 May 2013.
引用
- Robertson K, Marshman LAG, Hennessy M, et al. Pregabalin versus gabapentin in the treatment of sciatica: study protocol for a randomised, double-blind, cross-over trial (PAGPROS). Trials. 2018. PMID: 29316960. doi:10.1186/s13063-017-2400-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。